Obesity and vitamin D deficiency have both been linked to augmented activity of the tissue renin-angiotensin system (RAS). We investigated whether obesity status influenced the relationship between 25-hydroxyvitamin D (25(OH)D) and vascular RAS activity. The levels of 25(OH)D were measured in hypertensive obese (n ¼ 39) and non-obese (n ¼ 58) Caucasian individuals. RAS activity was assessed by plasma renin activity, and evaluation of the vascular sensitivity to angiotensin II (AngII) using the mean arterial pressure ( 
Introduction
Obesity and 25-hydroxyvitamin D (25(OH)D) deficiency are increasingly common epidemiological scenarios that have both been implicated with dysregulated control of the renin-angiotensin system (RAS). [1] [2] [3] [4] Obesity is considered to be a state of high RAS activity; adipocytes have been shown to produce all of the components of the RAS locally. [5] [6] [7] [8] [9] [10] [11] Excess activity of the RAS results in increased salt sensitivity, volume expansion, hypertension (HTN) and insulin resistance-all unfavourable characteristics of the obese state. 10, [12] [13] [14] Thus, hyperactivity of the RAS in obesity may represent a crucial target for cardiovascular risk modification.
Animal studies have strongly suggested that vitamin D negatively regulates the RAS by inhibiting renin. Mice lacking the vitamin-D receptor or 1a-hydroxylase enzyme develop a phenotype of increased RAS activity with resultant HTN and cardiac hypertrophy, which are improved with RAS antagonism and vitamin-D agonist therapy. [15] [16] [17] [18] [19] A similar inverse association between 1,25(OH) 2 D and plasma renin activity (PRA) was described by Resnick et al. 20 and Tomaschitz et al. 21 in humans. We recently observed an inverse association between 25(OH)D and the renal vascular sensitivity to angiotensin II (AngII) in humans, 22 linking 25(OH)D deficiency with increased activity of the renal vascular RAS. Prior investigations have used the renal vascular and blood pressure responses to exogenous AngII as an inversely proportional measure of vascular RAS activity. [23] [24] [25] [26] [27] [28] [29] Though 25(OH)D deficiency has been associated with both obesity and increased tissue RAS activity, [30] [31] [32] [33] the influence of obesity on the relationship between 25(OH)D and RAS regulation has not been described. Given the heightened tissue RAS activity in obesity and HTN, we hypothesized that the relationship between 25(OH)D and tissue RAS activity would be notably pronounced in obese subjects with HTN, when compared with non-obese subjects with HTN.
Methods

Participants
We performed a retrospective analysis of hypertensive subjects previously studied in the HyperPath cohort. The HyperPath Project was designed to characterize the physiology and genetic underpinnings of cardiovascular disease in an international cohort of patients. Participants were studied at four collaborating centres: Brigham and Women's Hospital (Boston, MA, USA), University of Utah Medical Center (Salt Lake City, UT, USA), Vanderbilt University Hospital (Nashville, TN, USA) and Hôpital European Georges Pompidou (Paris, France). Study protocols were approved by the Human Subjects Committees at each site, and informed written consent was obtained from each subject.
HTN was defined as an untreated seated diastolic blood pressure4100 mm Hg, a diastolic blood pressure490 mm Hg with one or more antihypertensive medications, or the use of two or more antihypertensive medications. All blood pressure measurements reflect the average of three readings with standard manual mercury sphygmomanometer. Anthropometric measurements were obtained on admission to each institute's clinical research centre. Exclusion criteria included chronic kidney disease, coronary heart disease, heart failure, suggested or known causes of secondary HTN and active malignancy. The full scope of inclusion and exclusion criteria of this population have been described previously. 34, 35 At the time of this retrospective analysis, 1248 subjects had been studied in the HyperPath cohort. A total of 810 of these subjects had HTN and 345 of these hypertensive subjects had available frozen plasma for further analysis. To avert erroneous interpretations of the RAS and its biological effect, only subjects known to have normal RAS physiology were considered for inclusion. On the basis of a dynamic phenotyping of these 345 subjects, 164 of them were previously classified as hypertensives who demonstrated normal circulating RAS physiology in response to sodium restriction and exogenous AngII infusion defined as: PRA elevation 42.4 ng ml À1 per h with upright posture and an aldosterone increase of 415 ng per 100 ml with AngII administration. This approach of studying an isolated phenotype of HTN, limits misinterpretations attributable to the heterogeneity of RAS regulation among subjects, especially when studying hypothesized modifiers of RAS such as obesity, vitamin D and HTN. A total of 97 of the 164 subjects completed the AngII infusion protocol (below), and had AngII-stimulated mean arterial pressure (MAP) information available for analysis.
All 97 subjects were of Caucasian race. Individuals with body mass index (BMI)X30 kg m À2 were considered 'obese,' whereas all individuals with BMI o 30 kg m À2 were considered 'non-obese.' This dichotomization of obesity status was pursued over further stratifications of BMI, as only 16 of the study participants had a lean BMI of o 25 kg m À2 .
Study protocol
To minimize interference with RAS assessment, participants taking angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or mineralocorticoid receptor antagonists were transitioned to amlodipine and/or hydrochlorothiazide at 3 months before study initiation. At 2 weeks before study initiation, all antihypertensive medications were withdrawn. Subjects were maintained on a fixed potassium (80 mmol per day), calcium (1000 mg per day) and high sodium (200 mEq per 24 h) diet for 4-7 days leading to study initiation. This dietary sodium content approximates the daily salt consumption in Western countries. 36, 37 External sodium balance and diet compliance were confirmed with a 24-h urine sodium excretion of X150 mmol.
Subjects were admitted to the clinical research centre and maintained in supine position for one night and one day. Baseline MAP was determined while supine between 0800 and 1000 h, following 10 h of overnight rest using the average of five readings from a Dinamap automated device (Critikon, Tampa, FL, USA). All subjects underwent infusion with AngII with 3 ng kg À1 per min for 55 min, with MAP readings recorded every 2 min. The AngII-stimulated MAP was defined as the average of five readings in the last 10 min of the infusion, and used as a measure for intrinsic systemic vascular RAS activity. Baseline blood sampling was also obtained in the morning following overnight rest, collected on ice and kept frozen until assayed.
Biochemical assessments
Blood samples collected during the study protocol were used to measure electrolytes and PRA. PRA was measured as previously described. 38 The level of 25(OH)D was measured from the baseline frozen blood samples obtained on the original day of study using the DiaSorin, Inc. radioimmunoassay (Stillwater, MN, USA). This assay has a sensitivity of 4 ng ml À1 with a coefficient of variation ranging from 4.4 to 8.4%. As 25(OH)D was measured from stored frozen samples, we thawed, aliquoted and measured 25(OH)D levels from 19 participants, who also had 25(OH)D levels measured on fresh samples from the original day of study. The correlation coefficient comparing levels from fresh and frozen samples was 0.97.
Statistical analyses
Analyses were conducted to evaluate the association between 25(OH)D concentrations and the MAP response to an infusion of AngII in the obese and non-obese subgroups separately, and thereafter to evaluate whether these relationships were significantly different. 
Results
Study population
Characteristics of the two study populations are shown in Table 1 . Obese individuals tended to have lower 25(OH)D levels and PRA, although this disparity was not statistically significant. There were no differences in baseline and AngII-stimulated MAP between obese and non-obese subjects. Table 2) .
Obesity as an effect modifier
In accordance with our findings, suggesting an interaction between obesity status and 25(OH)D in predicting the vascular sensitivity to AngII, we used an adjusted, continuous interaction model to evaluate whether increasing BMI was an effect modifier of the relationship between 25(OH)D and AngII-stimulated MAP. This multivariable model (adjusted for age, gender, BMI and baseline MAP) confirmed that the adjusted effect estimates for the obese and non-obese groups were significantly different (P-interaction ¼ 0.03, R 2 ¼ 0.55).
Discussion
Obesity and 25(OH)D deficiency are common pathologies in humans that have been increasingly observed to aggregate in tandem. [30] [31] [32] Despite the high prevalence of HTN in obesity, very little is understood regarding its mechanisms. Efforts to further elucidate underlying mechanisms of HTN in obesity, and/or simple and effective methods to regulate RAS in obesity, may have tremendous implications in preventative health. The epidemiological concurrence of obesity and 25(OH)D deficiency is relevant because both obesity [5] [6] [7] [8] 11 and 25(OH)D deficiency [15] [16] [17] [18] [19] 21, 22, [39] [40] [41] have been linked to augmented RAS activity, which is a known contributor to cardiovascular disease. 10, [12] [13] [14] Our investigation included a population of Caucasian hypertensive men and women, who were largely 25(OH)D insufficient (o30 ng ml À1 ) according to current convention. 3 We employed the MAP response to an infusion of AngII to evaluate vascular RAS activity, wherein vascular RAS activity is inversely proportional to the MAP response to AngII. When dichotomized by obesity status, both obese and non-obese subgroups had similar 25(OH)D concentrations, and similar MAP responses to AngII. In contrast, when the MAP response to AngII was evaluated as a function of 25(OH)D concentrations, we observed that 25(OH)D levels positively predicted the vascular sensitivity to AngII in obesity, but not in the non-obese. These findings may suggest that 25(OH)D deficiency in obesity may result in appreciably augmented vascular RAS activity, whereas with higher 25(OH)D levels vascular RAS activity may be decreased. In contrast, among the non-obese subjects in our study, variations in 25(OH)D levels may not result in detectable changes in vascular RAS activity.
Our findings are consistent with and extend those from prior reports. We detected an inverse association between circulating PRA and 25(OH)D levels that was not significant, suggesting that the relationship between 25(OH)D status and the RAS may not be adequately quantified by measuring traditional circulating RAS components when in high sodium balance. [22] [23] [24] [25] [26] [27] Although animal studies have provided convincing support for 1,25(OH) 2 D as an antagonist of renin expression, [15] [16] [17] [18] [19] there is a paucity of studies exploring the RAS regulatory role of vitamin D in humans, [20] [21] [22] with almost no attention to 25(OH)D deficiency in obesity. In concert with our current report, we recently demonstrated that 25(OH)D deficiency was associated with blunted renal vascular sensitivity to AngII in normotensive humans in high sodium balance. 22 Herein, we extend those findings by demonstrating that the influence of vitamin D on the vascular sensitivity to AngII may predominate in obesity. Furthermore, we demonstrate a similar inverse association between 25(OH)D and AngII sensitivity in the systemic vasculature. Taken together, our findings suggest the regulation of the vascular tissue RAS may be significantly influenced by the interaction of 25(OH)D and adiposity status.
To evaluate the role of body fat content in the complex relationship between adiposity, 25(OH)D status and RAS regulation, we explored whether BMI modified the relationship between 25(OH)D and vascular sensitivity to AngII. Continuous multivariable interaction analysis confirmed that increasing BMI significantly modified the relationship between 25(OH)D and the vascular sensitivity to AngII. These findings may suggest that with increasing adiposity, in which tissue RAS activity is suspected to increase, the RAS-inhibitory influence of vitamin D is detectable. In contrast, in non-obese subjects in whom baseline tissue RAS activity is considered to be lower, the RAS-inhibitory effect of vitamin D may be too low to detect, or negligible in high sodium balance.
Contrary to our findings in humans, previous studies have demonstrated the RAS inhibitory effects of vitamin D analogues by showing an inverse relationship between circulating PRA and biological vitamin D action. [15] [16] [17] 20, 21, 41 This disparity may be attributed to the fact that our study sample was small and was equilibrated on a PRA-suppressive high sodium diet. This diet-induced dampening of circulating PRA could reduce levels to the point in which small differences are not readily distinguished within our sample size. Alternatively, this observation may suggest that vitamin D regulation of the RAS in humans is best detected at the tissue level by 'the local RAS' or target organ AngII sensitivity. The role of the local RAS in vascular and organ structure pathology has gained significant credence, especially in adipose tissue, in which we observed the most pronounced effect. 9, 42 Our findings must be interpreted in the context of our study design. Our analysis was cross-sectional, and therefore cannot demonstrate causality or directionality. The analysed sample size was small, thus resultant positive and negative findings will require validation in a larger cohort. However, to our knowledge this is the first study focused on the role of 25(OH)D in regulating RAS in obesity, and was 3 our analysis was focused on evaluating the physiological effect of 25(OH)D concentrations on the vascular sensitivity to AngII at the time of study; therefore we did not adjust for these factors. Parathyroid hormone, circulating calcium and intracellular calcium have long been associated in a complex interaction with dietary sodium, dietary calcium, RAS activity and HTN. 47, 48 Though our study design controlled dietary sodium and calcium intake, because calcium and parathyroid hormone were not directly measured, we cannot comment on whether associations between 25(OH)D and RAS activation were independent of these factors.
In conclusion, vitamin D may have significant RAS regulatory effects in humans, especially in obese individuals with HTN. Deficiency of 25(OH)D, in the setting of obesity, may represent a state of heightened vascular RAS activity. Demonstrating that vitamin D favourably modulates the vascular sensitivity to AngII in obesity could provide substantial credence to the hypothesis that vitamin D deficiency in obesity heightens vascular tissue RAS activity, whereas its supplementation subdues it. Future prospective studies evaluating the effect of vitamin D supplementation in obesity could shed further insight on whether vitamin D may have a causal role in regulating tissue RAS activity.
